Dexcom Gains Approval For No-Calibration, 'Interoperable' CGM System
US FDA's March 27 de novo clearance of the Dexcom G6 integrated continuous glucose monitoring (iCGM) system for diabetics gives Dexcom a no-calibration offering, a first-in-class "interoperable" system and sets out a streamlined regulatory pathway for future CGM devices with similar features.
You may also be interested in...
It was another record year for novel device approvals by US FDA, driven by the big uptick in de novo classifications for low-to-moderate-risk devices in 2018. Meanwhile, original PMA approvals dropped significantly. An analysis and infographic on FDA device approval trends in 2018.
US FDA recently approved the first 90-day CGM system and expanded the labeling for a closed-loop system to treat diabetes.
An infographic to spotlight US FDA device approval trends during the first quarter, January through March.